

NRES Committee London - South East

Bristol Research Ethics Committee Centre
Level 3, Block B
Whitefriars,
Lewins Mead,
Bristol
BS1 2NT

Telephone: (0117) 3421382
Facsimile: (0117) 3420445

21 October 2013 – Re-issued 12.03.14

Professor Philip M. W. Bath
Professor of Stroke Medicine
University of Nottingham
Division of Stroke Medicine - Research Dept
Clinical Sciences Building
City Hospital Campus
Hucknall Road
Nottingham NG5 1PB

Dear Professor Bath

Study Title: Safety and tolerability of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke: a randomised controlled trial

REC reference: 08/H1102/112

Protocol number: 31350

EudraCT number: 2007-006749-42

Amendment number: SA03/13

Amendment date: 02 August 2013

Thank you for submitting the above amendment, which was received on 3 August 2013.

Research Site	Principal Investigator / Local Collaborator
North Middlesex University Hospital NHS Trust, Sterling Way, London N18 1QX	Dr Robert Luda
Imperial Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace, London W6 8 RF	Dr Olivia Geraghty
Western Health and Social Care Trust, Altnagelvin Area Hospital Site, Glenshane Road, Londonderry BT47 6SB	Dr John Corrigan
NHS Ayrshire & Arran, University Hospital Crosshouse, Kilmarnock KA2 0BE	Dr Imtiaz Shah
University Hospitals Coventry & Warwickshire, Dept of Neurology, Clifford bridge Road, Coventry CV2 2DX	Dr Anthony Kenton

Royal Albert Edward infirmary, Wrightington, Wigan & Leigh NHS Foundation Trust, Wigan Lane, Wigan, WN1 2NN	Dr Habib Rehman
NHS Lanarkshire, Hairmyres Hospital, Eggleston Road, East Kilbride G75 8RG	Dr Brigitte Yip
Salisbury NHS Foundation Trust, Salisbury District hospital, Odstock Road, Salisbury, Wiltshire SP2 8BJ	Dr Toby Black

The amendment relates solely to the addition of new site(s) and/or investigator(s) within the National Health Service (NHS) or Health and Social Care (HSC) in Northern Ireland. The site-specific assessment for the site(s) will therefore form part of the research governance review. The Site-Specific Information (SSI) Form for the site should be included with the application for R&D approval.

On behalf of the Committee, I am pleased to confirm the extension of the favourable opinion to the new site(s) and/or investigator(s), subject to management permission being given by the relevant NHS/HSC R&D office(s) prior to the study starting at the site.

Statement of compliance

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.


The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

08/H1102/112

Please quote this number on all correspondence

Yours sincerely



Mr Wai Yeung - REC Assistant

Email: nrescommittee.london-southeast@nhs.net

Copy to: *Mr Paul Cartledge*